Miles Minter's questions to Biogen Inc (BIIB) leadership • Q2 2025
Question
Jake, on for Miles Minter at William Blair, asked about the selzartamab opportunity in antibody-mediated rejection (AMR), how Biogen models the market, and the influence of competitor data on expansion strategies.
Answer
CEO Christopher Viehbacher estimated the addressable AMR market at approximately $1.5 billion annually and expressed confidence that selzartamab is positioned to be first-to-market. Priya Singhal, EVP & Head of Development, added that they are expanding into a fourth indication, late MBI, a newly classified rejection phenotype which represents an additional 5,000-6,000 patients and augments the overall opportunity.